I will try to discuss the position of the T-cell’s engagement in myeloma treatment in the near future. My recommendation will be to use them as early as possible. And the argumentation that I have, one, looking at historical data in single-agent myeloma drugs in Phase I to II studies, the response rates are between 20 to 35%, as to say, one-third of the patient will respond to, so, new single-agent myeloma drug...
I will try to discuss the position of the T-cell’s engagement in myeloma treatment in the near future. My recommendation will be to use them as early as possible. And the argumentation that I have, one, looking at historical data in single-agent myeloma drugs in Phase I to II studies, the response rates are between 20 to 35%, as to say, one-third of the patient will respond to, so, new single-agent myeloma drug.
While looking at these T-cell engager, we are using them in a very late stage patient. Often, they are refractory and penta-exposed. We see a response rate between 65, up to 85, as to say, they are very effective. And I will argue to use these drugs as early as possible, and try to minimize the time taken for this agent to reach the first-line treatment, but because I believe the most effective agents should be used in first-line in cancer patients.